Feasibility assessment of patient reporting of symptomatic adverse events in multicenter cancer clinical trials

JAMA Oncology

Volumn 3, Issue 8, 2017, Pages 1043-1050

  Basch, Ethan ^a,b   Dueck, Amylou C ^c   Rogak, Lauren J ^b   Minasian, Lori M ^d   Kelly, William Kevin ^e,f   O’Mara, Ann M ^d   Denicoff, Andrea M ^d   Seisler, Drew ^g   Atherton, Pamela J ^g   Paskett, Electra ^h   Carey, Lisa ^a   Dickler, Maura ^b   Heist, Rebecca S ⁱ   Himelstein, Andrew ^j   Rugo, Hope S ^k   Sikov, William M ^l,m   Socinski, Mark A ⁿ   Venook, Alan P ^k   Weckstein, Douglas J ^o   Lake, Diana E ^b   Biggs, David D ^j   Freedman, Rachel A ^p   Kuzma, Charles ^q   Kirshner, Jeffrey J ^r   Schrag, Deborah ^p   more..

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MAYO CLINIC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

^g MAYO CLINIC   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j HELEN F GRAHAM CANCER CENTER   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l WOMEN AND INFANTS HOSPITAL   (United States)

^m BROWN UNIVERSITY   (United States)

ⁿ FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^o New Hampshire Oncology Hematology   (United States)

^p DANA FARBER CANCER INSTITUTE   (United States)

^q Novant Health GWSM   (United States)

^r Hematology/Oncology Associates of Central New York   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ADULT; ADVERSE EVENT; AGED; ANOREXIA; ARTICLE; CANCER RESEARCH; CANCER THERAPY; CAUCASIAN; EDUCATIONAL STATUS; ERROR; ETHNIC DIFFERENCE; FATIGUE; FEASIBILITY STUDY; FEEDBACK SYSTEM; FEMALE; HAND FOOT SYNDROME; HISPANIC; HUMAN; INSTITUTIONAL ERROR; INTERNET; INTERNET CONNECTIVITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PAIN; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PATIENT REFUSAL; PATIENT REPORTING; RASH; SELF REPORT; SEX DIFFERENCE; SYMPTOMATIC ADVERSE EVENT; VOLUNTARY REPORTING; VOMITING; CLINICAL TRIAL; DRUG SURVEILLANCE PROGRAM; MIDDLE AGED; MULTICENTER STUDY; PATIENT-REPORTED OUTCOME; VERY ELDERLY; YOUNG ADULT;

ANTINEOPLASTIC AGENT;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; SELF REPORT; YOUNG ADULT;

EID: 85027891035     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.6749     Document Type: Article

References (46)

1. National Cancer Institute, National Institutes of Health, US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), version 3. http://ctep.cancer.gov/protocolDevelopment/electronic_applications /docs/ctcaev3.pdf. Published August 9, 2006. Accessed March 23, 2016.
2. Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007;25(32):5121-5127.
3. Atkinson TM, Li Y, Coffey CW, et al. Reliability of adverse symptom event reporting by clinicians. Qual Life Res. 2012;21(7):1159-1164.
4. Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? a comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol. 2004;22(17):3485-3490.
5. Pakhomov SV, Jacobsen SJ, Chute CG, Roger VL. Agreement between patient-reported symptoms and their documentation in the medical record. Am J Manag Care. 2008;14(8):530-539.
6. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362(10): 865-869.
7. Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006;7 (11):903-909.
8. Bruner DW, Bryan CJ, Aaronson N, et al; National Cancer Institute. Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute–sponsored clinical trials networks. J Clin Oncol. 2007;25(32):5051-5057.
9. Minasian L, O’Mara A. Introduction to special JNCI monograph on patient-reported outcomes. J Natl Cancer Inst Monogr. 2007;(37):5063-5069.
10. Ganz PA, Gotay CC. Use of patient-reported outcomes in phase III cancer treatment trials: lessons learned and future directions. J Clin Oncol. 2007;25(32):5063-5069.
11. Lipscomb J, Reeve BB, Clauser SB, et al. Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. J Clin Oncol. 2007;25(32):5133-5140.
12. Rock EP, Kennedy DL, Furness MH, Pierce WF, Pazdur R, Burke LB. Patient-reported outcomes supporting anticancer product approvals. J Clin Oncol. 2007;25(32):5094-5099.
13. Wu AW, Snyder C, Clancy CM, Steinwachs DM. Adding the patient perspective to comparative effectiveness research. Health Aff (Millwood). 2010; 29(10):1863-1871.
14. Cella D, Riley W, Stone A, et al; PROMIS Cooperative Group. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol. 2010;63(11):1179-1194.
15. US Department of Health and Human Services, Food and Drug Administration. Guidance for industry: patient-reported outcomes measures—use in medical product development to support labeling claims. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation /Guidances/UCM193282.pdf. Published December 2009. Accessed March 24, 2014.
16. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Pre-authorisation evaluation of medicines for human use: reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. https://www.ispor.org/workpaper/emea-hrql-guidance.pdf. Published January 2005. Accessed March 24, 2014.
17. Wagner LI, Zhao F, Chapman J-AW, et al. Patient-reported predictors of early treatment discontinuation: NCIC JMA.27/E1Z03 quality of life study of postmenopausal women with primary breast cancer randomized to exemestane or anastrozole. Paper presented at: San Antonio Breast Conference; December 9, 2011; San Antonio, TX.
18. Bhattacharya D, Easthall C, Willoughby KA, Small M, Watson S. Capecitabine non-adherence: exploration of magnitude, nature and contributing factors. J Oncol Pharm Pract. 2012;18(3):333-342.
19. Eliasson L, Clifford S, Barber N, Marin D. Exploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribed. LeukRes. 2011;35(5):626-630.
20. Timmers L, Boons CC, Mangnus D, et al. The use of erlotinib in daily practice: a study on adherence and patients’ experiences. BMC Cancer. 2011;11:284.
21. Bruner DW, Hanisch LJ, Reeve BB, et al. Stakeholder perspectives on implementing the National Cancer Institute’s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Transl Behav Med. 2011;1(1):110-122.
22. Basch E, Artz D, Dulko D, et al. Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol. 2005;23(15):3552-3561.
23. Basch E, Iasonos A, Barz A, et al. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol. 2007;25(34):5374-5380.
24. Basch E, Artz D, Iasonos A, et al. Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. J Am Med Inform Assoc. 2007;14(3):264-268.
25. clinicaltrials.gov. Paclitaxel, Nab-Paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer. NCT00785291. https://clinicaltrials.gov/ct2/show/NCT00785291. Accessed January 8, 2017.
26. clinicaltrials.gov. Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer. NCT00601900. https://clinicaltrials.gov/ct2/show/NCT00601900. Accessed January 8, 2017.
27. clinicaltrials.gov. Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery. NCT00770809. https://clinicaltrials.gov/ct2/show/NCT00770809. Accessed January 8, 2017.
28. clinicaltrials.gov. Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery. NCT00861705. https://clinicaltrials.gov/ct2/show/NCT00861705. Accessed January 8, 2017.
29. clinicaltrials.gov. Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer. NCT00265850. https://clinicaltrials.gov/ct2/show/NCT00265850. Accessed January 8, 2017.
30. clinicaltrials.gov. Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy. NCT00693992. https://clinicaltrials.gov/ct2/show/NCT00693992. Accessed January 8, 2017.
31. clinicaltrials.gov. Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer. NCT00698815. https://clinicaltrials.gov/ct2/show/NCT00698815. Accessed January 8, 2017.
32. clinicaltrials.gov. Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy. NCT00110214. https://clinicaltrials.gov/ct2/show/NCT00110214. Accessed January 8, 2017.
33. clinicaltrials.gov. Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement. NCT00869206. https://clinicaltrials.gov/ct2/show/NCT00869206. Accessed January 8, 2017.
34. Dueck AC, Mendoza TR, Mitchell SA, et al; National Cancer Institute PRO-CTCAE Study Group. Validity and reliability of the US National Cancer Institute’s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol. 2015;1(8):1051-1059.
35. Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute’s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9):dju244.
36. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-174.
37. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
38. clinicaltrials.gov. PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery. NCT01515787. https://clinicaltrials.gov/ct2/show/NCT01515787. Accessed January 8, 2017.
39. clinicaltrials.gov. Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy for Lung Cancer. NCT01262560. https://clinicaltrials.gov/ct2/show/NCT01262560. Accessed January 8, 2017.
40. clinicaltrials.gov. A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer. NCT02037529. https://clinicaltrials.gov/ct2/show/NCT02037529. Accessed January 8, 2017.
41. clinicaltrials.gov. Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer. NCT02414646. https://clinicaltrials.gov/ct2/show/NCT02414646. Accessed January 8, 2017.
42. Basch E, Wood WA, Schrag D, et al. Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial. Clin Trials. 2016;13(3):331-337.
43. Kluetz PG, Slagle A, Papadopoulos EJ, et al. Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms. Clin Cancer Res. 2016;22(7):1553-1558.
44. Judson TJ, Bennett AV, Rogak LJ, et al. Feasibility of long-term patient self-reporting of toxicities from home via the internet during routine chemotherapy. J Clin Oncol. 2013;31(20):2580-2585.
45. Broderick JE, Schwartz JE, Vikingstad G, Pribbernow M, Grossman S, Stone AA. The accuracy of pain and fatigue items across different reporting periods. Pain. 2008;139(1):146-157.
46. Schneider S, Broderick JE, Junghaenel DU, Schwartz JE, Stone AA. Temporal trends in symptom experience predict the accuracy of recall PROs. J Psychosom Res. 2013;75(2):160-166.